Related references
Note: Only part of the references are listed.Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Christian Buske et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation
Martina Ferrante et al.
DIAGNOSTICS (2021)
CXCR4 mutational status does not impact outcomes in patients with Waldenstrom macroglobulinemia treated with proteasome inhibitors
Jorge J. Castillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Genomic Landscape of Waldenstrom Macroglobulinemia and Its Impact on Treatment Strategies
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study
Roger G. Owen et al.
LANCET HAEMATOLOGY (2020)
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM).
Ramón Garcia-Sanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
Francesca Castellani et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Consensus Statement on the Management of Waldenstrom Macroglobulinemia Patients During the COVID-19 Pandemic
Dipti Talaulikar et al.
HEMASPHERE (2020)
Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenstrom's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE™ Trial
Judith Trotman et al.
BLOOD (2020)
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Joseph Mikhael et al.
BLOOD (2019)
High-dose therapy with autologous stem cells transplantation in Bing-Neel syndrome: A retrospective analysis of 14 cases
Laurence Simon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
How I treat Waldenstrom macroglobulinemia
Meletios A. Dimopoulos et al.
BLOOD (2019)
How we manage Bing-Neel syndrome
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg v41, 2018)
E. Kastritis et al.
ANNALS OF ONCOLOGY (2019)
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
Jorge J. Castillo et al.
BLOOD (2019)
Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features
Juliette Svahn et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia
Jonas Paludo et al.
ANNALS OF HEMATOLOGY (2018)
Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine
Richa Manwani et al.
BLOOD (2018)
Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenstrom macroglobulinemia
Daniela Drandi et al.
HAEMATOLOGICA (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenstrom macroglobulinemia
Daniela Drandi et al.
HAEMATOLOGICA (2018)
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients
Romanos Sklavenitis-Pistofidis et al.
BLOOD (2018)
Treatment of AL amyloidosis with bendamustine: a study of 122 patients
Paolo Milani et al.
BLOOD (2018)
First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival
Tomas Pika et al.
BLOOD (2018)
Pattern of somatic mutations in patients with Waldenstrom macroglobulinemia or IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni et al.
HAEMATOLOGICA (2017)
Ibrutinib for patients with rituximab-refractory Waldenstrm's macro globulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Pattern of somatic mutations in patients with Waldenstrom macroglobulinemia or IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni et al.
HAEMATOLOGICA (2017)
Diagnosis and Management of Waldenstrom Macroglobulinemia Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016
Prashant Kapoor et al.
JAMA ONCOLOGY (2017)
Bing-Neel Syndrome: Illustrative Cases and Comprehensive Review of the Literature
Marzia Varettoni et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2017)
Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel
Shirley D'Sa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia
Veronique Leblond et al.
BLOOD (2016)
European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis
Sajitha Sachchithanantham et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia
Houry Leblebjian et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
Meletios A. Dimopoulos et al.
BLOOD (2013)
MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
Lian Xu et al.
BLOOD (2013)
Diagnostic Challenges of Amyloidosis in Waldenstrom Macroglobulinemia
Giovanni Palladini et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy
Jean-Marc Leger et al.
NEUROLOGY (2013)
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
Christopher P. Venner et al.
BLOOD (2012)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Treatment of IgM-Associated AL Amyloidosis With the Combination of Rituximab, Bortezomib, and Dexamethasone
Giovanni Palladini et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia
Irene M. Ghobrial et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenstrom Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Charalampia Kyriakou et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Allogeneic Stem-Cell Transplantation in Patients With Waldenstrom Macroglobulinemia: Report From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Charalampia Kyriakou et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
Christine I. Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
